drugset / Trial / NCT00564772

Raltegravir Kaletra Pharmacokinetics

NCT00564772

Phase 4 Completed 15 enrolled Allina Health System
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This will be an open-label, 3-period, fixed sequence study in young, healthy, male and female subjects of the pharmacokinetic interaction between raltegravir and Kaletra.

Timeline

Start
2007-11
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lopinavir Other / unclassified
Subject Raltegravir Other / unclassified 400 mg
Subject Ritonavir Other / unclassified

Indications

No indication recorded.